Xencor (NASDAQ:XNCR) had its price objective trimmed by Nomura to $28.00 in a research report report published on Thursday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Several other brokerages also recently issued reports on XNCR. BidaskClub raised Xencor from a buy rating to a strong-buy rating in a research note on Friday, March 9th. Zacks Investment Research downgraded Xencor from a hold rating to a sell rating in a research note on Thursday, March 8th. Wedbush increased their price objective on Xencor from $38.00 to $39.00 and gave the stock an outperform rating in a research note on Monday, March 19th. Cantor Fitzgerald reissued an overweight rating and issued a $37.00 price objective on shares of Xencor in a research note on Thursday, March 1st. Finally, ValuEngine raised Xencor from a hold rating to a buy rating in a research note on Monday, April 2nd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Xencor has an average rating of Buy and an average price target of $35.17.
Shares of NASDAQ XNCR opened at $28.41 on Thursday. Xencor has a 12 month low of $18.55 and a 12 month high of $34.63. The firm has a market cap of $1,542.72, a PE ratio of -27.06 and a beta of 1.51.
Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. Xencor had a negative return on equity of 16.62% and a negative net margin of 137.35%. The business had revenue of $10.94 million during the quarter, compared to the consensus estimate of $15.65 million. sell-side analysts anticipate that Xencor will post -2.09 EPS for the current year.
In related news, insider Paul A. Foster sold 5,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.01, for a total value of $125,050.00. Following the completion of the sale, the insider now directly owns 7,419 shares of the company’s stock, valued at approximately $185,549.19. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul A. Foster sold 10,000 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total value of $260,300.00. Following the completion of the sale, the insider now directly owns 12,419 shares of the company’s stock, valued at $323,266.57. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,000 shares of company stock valued at $3,101,550. Company insiders own 4.03% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Great West Life Assurance Co. Can raised its stake in shares of Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 4,005 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Xencor during the 3rd quarter worth about $201,000. UBS Asset Management Americas Inc. purchased a new stake in shares of Xencor during the 4th quarter worth about $205,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Xencor during the 4th quarter worth about $220,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Xencor during the 4th quarter worth about $278,000. 79.49% of the stock is owned by institutional investors.
WARNING: “Nomura Cuts Xencor (XNCR) Price Target to $28.00” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/09/nomura-cuts-xencor-xncr-price-target-to-28-00.html.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.